26.11.2012 Views

Peptide-Based Drug Design

Peptide-Based Drug Design

Peptide-Based Drug Design

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Proline-Rich Antimicrobial <strong>Peptide</strong>s 173<br />

which is within the most conserved region of the protein in different Gramnegative<br />

species. This corresponds to the short hydrophilic EAA sequence<br />

motif that is highly conserved in ABC import systems, and is localized in a<br />

cytoplasmic loop that constitutes an important interaction site with the cognate<br />

ABC-ATPase subunit (24). Taking everything into account, the hypothesis that<br />

SbmA may be an uptake system carrying compounds into the bacterial cells<br />

is quite solid, and PRPs appear to use it to be internalized into bacterial cells<br />

(21,25).<br />

In conclusion, our genetic approach has allowed us to demonstrate that the<br />

entrance of PRPs into Gram-negative bacterial cells is not simply mediated by<br />

the intrinsic capacity of these peptides to cross the membrane lipid bilayers,<br />

but that a specific protein–mediated transport mechanism is necessary. Our data<br />

clearly indicate that SbmA is involved in the transport of peptides and that it<br />

likely represents an important part of this process, as its inactivation leads to<br />

an increased resistance to PRPs. This type of bacterial transporters may thus<br />

represent a Trojan horse for translocation of specific peptides into bacterial cells.<br />

This also suggests possible novel strategies for using PRPs or their analogs as<br />

shuttle systems for the internalization of non-permeant drugs with anti-infective<br />

potential into bacteria.<br />

4. Notes<br />

1. By this approach, positive clones are expected to arise from overexpression of<br />

wild-type genes conferring resistance or from trans-dominant mutations giving a<br />

mutant (resistant) phenotype (14). To identify loss-of-function recessive mutations<br />

the method should be reversed: P-RES resistant clones should be transformed with<br />

a genomic library constructed with the DNA of the wild-type HB101, and clones<br />

with restored peptide susceptibility analyzed.<br />

2. Isogenicity between the wild type strain and the mutated colonies may be checked<br />

by ERIC-PCR based on the enterobacterial repetitive intergenic consensus<br />

(ERIC) sequences (26). Genomic DNA is extracted and amplified by PCR with<br />

the specific primer 5 ′ -AAGTAAGTGACTGGGGTGAGCG-3 ′ for the conserved<br />

ERIC sequence. Amplified PCR products are separated by electrophoresis on 2%<br />

agarose gel and the band patterns compared with those of the parental HB101<br />

strain. A nonisogenic E. coli strain may be used as a control.<br />

3. To obtain highly purified DNA samples, an additional extraction with<br />

phenol/chloroform followed by one with chloroform may be performed. The<br />

DNA is then precipitated by adding NaCl to a final concentration of 0.3 M and<br />

2.5 volumes of 100% ethanol. After centrifugation, the pellet is washed twice<br />

with 70% ethanol, dried on air and resuspended in sterile water. This additional<br />

procedure greatly increases the efficiency of transformation.<br />

4. The plasmid library can be subjected to a round of amplification using the E. coli<br />

XL-1 Blue strain before being introduced into the final strain. In this case, the

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!